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1Abstract
Objectives
Axillary reverse mapping (ARM) is a technique to map and preserve arm lymphatics which may be
damaged during surgery, resulting in lymphoedema.
This work systematically reviews the incidence of lymphoedema following sentinel lymph node
biopsy (SLNB) + ARM, compared to SLNB alone, for clinically node negative disease, as well as
recurrence rate, other morbidity and the feasibility and difficulties of ARM.
Materials and Methods
The following databases were searched: PubMed, Embase, Cochrane Library. Abstracts submitted to
recognised societies dedicated to research in oncology were included. Studies were eligible if
performed within the last 10 years; ARM was used in any form; ARM performed during SLNB +/-
axillary lymph node dissection (ALND). Studies were analysed using Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Results
No studies were found meeting the initial inclusion criteria. Therefore, studies reporting use of SLNB
+ ARM (i.e. no comparison to SLNB) were reviewed. A second search was performed to identify
studies reporting outcome following SLNB alone. Twelve studies reported data on patients
undergoing SLNB + ARM and 23 studies on patients undergoing SLNB. Incidence of lymphoedema
following SLNB + ARM was quoted between 0-4% and 0–63.4% following SLNB. Few studies
commented on recurrence rate. Studies included were of mainly low level of evidence.
Conclusion
Evidence is beginning to emerge for the use of ARM in order to reduce lymphoedema following
axillary surgery. However, data regarding oncological safety of ARM is not clear and randomised
controlled trials, with adequate follow-up, need to be performed to determine this.
2Introduction
History
At the turn of the century, breast cancer treatment in the UK moved from axillary lymph node
dissection (ALND) [1] to four-node axillary sampling [3]. Even with this reduction in lymph node
removal, it was estimated that 60-70% of patients with early breast cancer have no axillary disease
and therefore, preservation of these lymph nodes outweighs removal [1, 4]. In the last ten years or so
[5, 6] the concept of selecting only the first lymph node(s) draining the breast – the sentinel lymph
node(s), has become commonplace. Current National Institute for Health and Care Excellence (NICE)
guidance [7] states that minimally invasive surgery should be performed where possible for patients
with no evidence of lymph node involvement and this should be by sentinel lymph node biopsy
(SLNB).
Lymphoedema
The reported incidence of lymphoedema following ALND ranges from 6% to as high as 77% [1].
SLNB has helped to reduce the incidence of lymphoedema to between 2 - 7%, without impacting on
overall survival [8, 9].
The Axillary Lymphatic Mapping Against Nodal Axillary Clearance (ALMANAC) multicentre
randomised trial in clinically node-negative breast cancer patients, compared those who underwent
SLNB (n = 515) to those who received standard axillary staging procedure (n = 516) [10]. SLNB was
associated with reduced arm morbidity and better quality of life over a 12-month period, with no
compromise in efficacy, measured by axillary recurrence rate, local recurrence and survival.
Data on comparable survival between patients undergoing ALND and those having SLNB alone, has
been demonstrated in the Phase III study Z0011 trial by The American College of Surgeons Oncology
Group [11]. This prospective multi-centre trial compared overall survival between patients with
positive sentinel lymph nodes, randomised to receive either ALND or no further axillary treatment
3following SLNB. At 1 year, lymphoedema was reported subjectively by 13% (37 of 288) of patients
after SLNB + ALND and 2% (6 of 268) after SLNB alone (p<0.001). There were no significant
differences between the two groups for overall survival, disease-free survival, 5 year in-breast or
nodal recurrence.
Concept of axillary reverse mapping
It is hypothesised that there are distinct non-overlapping nodes which drain the arm and the breast
respectively [12]. Therefore, by tracing the two different pathways, a technique known as axillary
reverse mapping (ARM), it is theoretically possible to resect axillary nodes alone and their draining
lymphatics from the breast, subsequently leading to a reduced rate of lymphoedema occurrence
following axillary surgery.
ARM involves injection of a radioactive substance, by blue dye, fluorescent dye or radioisotope into
the axilla, to highlight the lymphatic drainage pattern of the upper limb. Therefore, lymphatics
draining solely the arm can be avoided, as far as clinically able and lymphatics draining the breast
alone can be removed as clinically indicated [13].
ARM can be used in N0 patients requiring SLNB or N+ patients requiring ALND.
Oncological safety of ARM
Studies to date suggest that ARM is feasible in clinical practice [13, 14]. Data regarding safety in
terms of recurrence; disease-free survival; and absolute benefit in preventing lymphoedema, is
lacking. The hypothesis of this review is that the incidence of lymphoedema following SLNB + ARM
compared to SLNB alone will be significantly reduced, without increasing regional recurrence of the
disease.
4Methods and results
This research undertook the form of a systematic review of the literature.
Following the initial search strategy as will be described, there were no articles found making
comparisons between SLNB + ARM and SLNB alone, for clinically node negative disease. However,
there were studies which did investigate the use of SLNB + ARM on its own, either as descriptive
studies or compared to ALND + ARM.
In order to compare the incidence of lymphoedema following SLNB + ARM to SLNB alone, a second
literature review was conducted looking at SLNB alone and data collected on incidence of
lymphoedema, recurrence rate and other reported morbidity.
The data from the two searches were then compared.
5SEARCH 1 - Methods
Search strategy
Studies reporting use of ARM in SLNB procedures compared to SLNB alone, were reviewed. The
following online databases were searched for relevant literature: PubMed, Embase, Cochrane Library.
Abstracts submitted to recognised international societies dedicated to research in oncology, including
the American Society of Clinical Oncology, the San Antonio Breast Cancer Symposium and the St.
Gallen Oncology Conferences, available online, were included.
SLNB has become commonplace in routine practice in the last decade, therefore, the search was
limited to those studies published within the past 10 years (1st December 2005 – 31st December 2015).
Studies were restricted to those published in English language and performed in humans. The last
search was conducted on 7th February 2016.
The search terms used were: axillary reverse mapping, breast cancer, lymphoedema, sentinel lymph
node biopsy.
Inclusion criteria:
 Performance of ARM defined as simultaneous mapping of the breast and axilla
 ARM performed during SLNB with or without completion ALND
 Clinical trial using patient data
 Full-text article or abstract
Exclusion criteria:
 Studies which failed to fulfil inclusion criteria or ARM not used in methodology
 No relation to breast cancer
 Patient data not used
6 Duplicate study
 Restricted access to study report/data
 Review article, letter to the editors, editorial report, case report
Data extraction
Data was extracted from the selected studies using a data extraction form. All data was extracted
directly from the study text. No further statistical analysis was made where data was not presented.
Data was collected on: publication details; study design; number of participants; number undergoing
SLNB/ALND; follow-up period; participant age; ARM technique; stage of tumour; primary breast
cancer treatment; ARM node or lymphatics identification and preservations rate; ARM crossover
node identification rate; excised ARM nodes and node-positive rate; method of measurement of
lymphoedema, incidence of lymphoedema; in-breast and in-axillary recurrence rates; other reported
morbidity following the procedure: sensory disturbance; pain; impairment of arm mobility;
uniqueness of the study; limitations of study.
Critical appraisal
Once relevant studies were identified and data collected, the studies were assessed using the system
proposed by Harbour and Miller [15]. The quality of cohort studies was assessed using the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [16]. Risk of bias
was assessed using the Cochrane Collaboration’s tool for assessing risk of bias [17].
Statistical analysis
All extracted data were tabulated and presented as percentages.
7SEARCH 1 – Results
Using the initial search strategy, no studies were found meeting the inclusion criteria as outlined
above (Figure 1).
As no studies were found comparing SLNB + ARM to SLNB procedures alone, studies which
included a group of patients undergoing SLNB + ARM, without comparison to SLNB alone, were
analysed. Twelve full-text articles or abstracts were therefore, analysed in further detail (Tables 1 and
2).
Summary Search 1
A total of 12 studies describing the use of ARM during SLNB were eligible for discussion. One of
these was a systematic review. The remaining 11 studies were prospective cohort studies.
Overall incidence of lymphoedema following SLNB + ARM was reported between 0 and 6%.
Recurrence rate was reported between 0 and 1.2% for local recurrence and between 0 and 6.4% for
distant recurrence. Most studies reported semi-permanent tattooing from injection of blue dye in the
arm, lasting for up to one year. There were no other major reported morbidities. All studies were able
to successfully implement ARM into their clinical practice, without major difficulty.
8SEARCH 2 – Methods
As no studies were identified comparing SLNB + ARM to SLNB alone, studies reporting incidence of
lymphoedema following SLNB were reviewed. The following databases were used to obtain
evidence: PubMed, Embase, Cochrane Library. The following search terms were used: incidence,
sentinel lymph node biopsy, lymphoedema, breast cancer.
Again, the search was limited to those studies published within the past 10 years (1st December 2005
– 31st December 2015). Studies were restricted to those published in English language and performed
in humans. The last search was conducted on 7th February 2016.
Inclusion criteria:
 Able to determine group on which SLNB was performed
 Clinical trial using patient data
 Full-text article or abstract
Exclusion criteria:
 Studies which failed to fulfil inclusion criteria or SLNB not used in methodology
 Duplicate study
 Patient data not used
Data extraction
Data was collected on: publication details; study design; number of participants; follow-up period;
participant age; SLNB technique; stage of tumour; method of measurement of lymphoedema;
incidence of lymphoedema; in-breast and in-axillary recurrence rates; other reported morbidity
following the procedure: sensory disturbance; pain; impairment of arm mobility.
Critical appraisal and statistical analysis was performed as per Search 1 methodology.
9SEARCH 2 - Results
Using the second search strategy, a total of 23 studies meeting the inclusion criteria were identified
(Figure 2).
Summary – Search 2
23 studies are presented in this appraisal (Table 3). Two of these studies were systematic literature
reviews and the remainder were cohort studies – 8 of these were performed retrospectively and 13
prospectively.
Overall incidence of lymphoedema in patients undergoing SLNB in these studies was quoted between
0 and 63.4%. Local recurrence rate was quoted between 0% and 1% with systemic recurrence at 8%.
A number of other morbidities following SLNB procedure have been documented, including:
tattooing at site of blue dye injection; decreased arm function; seroma formation; sensory changes.
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Discussion
The results from both Search 1 and Search 2 are discussed in comparison below.
General overview
Overall incidence of lymphoedema following SLNB + ARM was quoted between 0 and 4%.
Incidence of lymphoedema following SLNB was found to be as high as 63.4%. The studies included
in the initial literature review were generally of a low level of evidence; there was only one systematic
literature review and no randomised controlled trials. The studies meeting the inclusion criteria for the
second search were again of a relatively low level of evidence; two systematic literature reviews and
no randomised controlled trials. It was felt that the data between the two searches were of similar
levels of evidence and therefore, comparable.
Comparability of studies
It is noted that the role of ARM is different between studies; ARM can be used in N0 patients
undergoing SLNB or N+ patients requiring ALND. Where this information is provided in the study
literature, the authors have been able to differentiate between these two groups (see tables).
It is difficult to compare the individual studies included in the initial literature review due to
differences in ARM methodology and measurement of lymphoedema. The studies by Kang S et al
[25] and Tummel E et al [29] were presented in the form of abstracts, with the remainder being full-
text articles. Therefore, less information regarding methodology and findings are given in these two
studies.
Regarding the literature review by Ahmed M et al [18] it is difficult to draw conclusions about the
overall rate of lymphoedema due to wide variation in methods and timing of measurement. Only one
of the studies included was a randomised controlled trial. Recurrence rate was reported by few studies
and length of follow-up mainly short-term. It was noted that when performing the ARM technique,
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the standard SLNB technique of dual mapping with radioisotope and blue dye is not being used and
use of ARM in less experienced units could therefore result in lower sentinel node detection rates.
It is difficult to make comparisons with studies which used less well known methods of ARM such as
the study by Ding X [19] who used lymphoscintigraphy and Sakurai T et al [22] and Noguchi M et al
[27] who used ICG fluorescence. Sakurai T et al [22] base their methodology and definition of
lymphoedema on the literature published by the Japanese Breast Cancer Society [50], specific to
characteristics of the Japanese population. Therefore, this may not translate to other cohorts.
It is noted that in the second search, again multiple methods were used for measurement of
lymphoedema.
Lymphoedema
Data regarding incidence of lymphoedema was reported in 10 out of the 12 studies in the first search.
In the cohort studies, detection of ARM nodes during SLNB (for N0 disease) ranged from 27-75%
with overall incidence of lymphoedema reported as 0-4%. In the systematic review [18] figures for
ARM detection were 27-100% and lymphoedema 0-6%. There was wide variation in method and
timing of measurement of lymphoedema, as well as overall follow-up.
All 10 studies gave some description as to how lymphoedema was measured, ranging from brief
description to repeatable, detailed instructions. The studies by Ochoa D et al [21], Tummel E et al;
[23] and Boneti C et al [28] described using water volume displacement, with the remaining studies
using some form of circumferential arm measurement. The methods used by Ochoa D et al [21] and
Boneti C et al [28] appear to be similar. Ochoea D et al [21] used the protocol from the National
Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 for arm volume measurements and the
International Society of Lymphology guidelines [53, 54] Boneti C et al [28] do not reference their
method. Unfortunately, as Tummel E et al [23] present only an abstract, their methodology is not
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given. Detection of ARM nodes in these three studies is 33.7%, 33.3% and 40.6% respectively, with
incidence of lymphoedema at 2.5%, 0.33% and 0%.
For the studies using circumferential arm measurements, again there is much variation. Ding X [26]
and Kang S et al [25] state that measurements are made but do not detail anatomical landmarks for
these. The remaining studies detail anatomical landmarks with Kuusk U et al [20] and Casabona F et
al [29] using an increase of >1cm from baseline as confirmation of lymphoedema and Sakurai T et al
[22] and Connor C et al [24] using >2cm. Detection of ARM nodes in these studies ranges from 27-
63.3% with lymphoedema incidence from 0-4%.
There appears to be greater detection of ARM nodes in the studies using circumferential arm
measurements for lymphoedema monitoring, but increased rates of lymphoedema detected. This is
converse to what would be expected; if more ARM nodes were detected (assuming they were
preserved), there should be a lower rate of lymphoedema.
Sakurai T et al [22] and Noguchi M et al [27] use a method of SLNB/ARM which is unique to the
study group [32], using preoperative lymphoscintigraphy and intraoperative radioisotope by ICG
fluorescence for ARM detection. All other studies use the conventional method of subareolar injection
of colloid and injection of blue dye into the arm. Sakurai T et al [22] report an ARM detection rate of
32.3% with no cases of lymphoedema detected, which is in keeping with the results from the other
studies. They report 5 cases of lymphoedema which all occurred when the ARM was also the SLN.
As this is a presented abstract only, exact incidence and individual cases are not discussed.
It is difficult to make comparisons between the above studies, as noted in the literature review by
Ahmed M et al [18] due to the variation in methodology. However, different methods of SLNB/ARM
produce similar results, but measurement of lymphoedema by water volume displacement compared
to circumferential arm measurements, detects a lower rate of lymphoedema. It is unclear which
method is the more accurate.
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According to the international consensus ‘Best Practice for the Management of Lymphoedema [55]’,
published in 2006 and in a more recent review by Armer J et al [56] several staging systems for
lymphoedema have been devised, including the International Society of Lymphology System, which
classifies lymphoedema according to visual changes. They admit that no one method of measurement
has achieved international agreement and each has its limitations, but suggest that water volume
displacement is the gold standard method for calculating limb volume, however, circumferential
measurements are the most commonly used.
The consensus states that circumferential limb measurements can be reliable if a standard protocol is
followed. They suggest taking the measurement on the ulnar aspect of the arm and recording the
distance from the nail bed of the little finger to 2cm above the ulnar styloid (wrist) and thus at 4cm
intervals from the starting point to 2cm below the axilla. A simplified method is also proposed that
requires taking measures at: around dorsum of hand, 10cm below the point of the elbow (olecranon
process); 10cm above the olecranon process.
The consensus states that lymphoedema is considered if the volume of the swollen limb is more than
10% greater than that of the contralateral unaffected limb and goes on to suggest classification into
‘mild’ ‘moderate’ or ‘severe’ categories, with limb volume <20%, 20-40% and >40% respectively.
It is clear from this present review, that some elements from the International Consensus are being
considered when forming methodology for these studies, but not strictly adhered to.
Regardless of difficulty in comparing individual studies as mentioned above, there is a clear
difference in reported rates of lymphoedema following SLNB alone (0-63.4%) compared to SLNB +
ARM (0-4%). Looking at the studies commenting on lymphoedema following SLNB alone, 10 of the
22 studies (45%) had rates of ≤5%. In 7 out of 9 (78%) studies commenting on lymphoedema 
following SLNB + ARM, had rates of ≤5%. This may have significant clinical implications on 
axillary surgery, should the method prove to be oncologically safe.
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Recurrence rate
A total of 8 of the studies in the first search gave information regarding number of nodes excised. For
SLNB alone, number of nodes excised varied between 0 and 5. This compares to between 9 and 45
for ALND. Only 4 studies commented on recurrence rate.
Kuusk U et al [20] reported that there were no axillary recurrences in their study group. This group
had a crossover rate (ARM node equivalent to SLN) of 9.6% and these nodes were positive for
malignancy in 2% of cases. They report that one patient died before 24 months of an unrelated
metastatic head and neck squamous cell carcinoma. This is the smallest study to report on recurrence
rate.
The study by Ochoa D et al [21] provides information on axillary recurrence as well as distant and
local recurrence. In this study crossover rate was 4.3% and these were positive for malignancy in
14.3%. Overall, ARM nodes were positive for malignancy in 18.5% of cases. Ochoa D et al [21] state
that blue lymphatics were identified in a total of 173 patients and were able to be preserved in 79.2%.
In this group where the lymphatics were preserved, there were 11 (6.4%) distant recurrences and 2
(1.2%) local recurrences. There was one axillary recurrence over an average follow-up of 12 months
which was found at 17 months of follow-up in a patient in which blue dye was not identified and
therefore no blue nodes were specifically preserved. The authors note that this patient underwent
surgery for T2N1 disease and had known metastatic spread to the liver.
Tummel E et al [23] and Kang S et al [25] both present abstracts which identify no axillary
recurrences and no locoregional recurrences respectively. Tummel E et al [23] is the largest study to
report on recurrence rate. Due to the nature of these reports, details regarding positivity of ARM and
crossover nodes are lacking.
It is difficult to make comparisons between these studies as they have different follow-up periods and
comment on different measures of recurrence. The study by Ochoa D et al [21] provides us with the
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most information and is of a generous sample size. Predicted recurrence rate is clearly related to stage
of the disease and this is only reported in Ochoa’s paper. However, the authors felt that this fairly
large trial with good length of follow-up is a surrogate for the safety of ARM. This is particularly true
for patients with 4N+ who receive radiation therapy anyway.
The Z0011 trial which has been previously mentioned [11] is a prospective multi-centre trial
comparing patients who had SLNB alone or ALND, following positive sentinel lymph nodes. They
report a local recurrence rate following SLNB of 1.8% and regional recurrence rate of 0.9% with no
significant differences between the two groups for overall survival, disease-free survival and 5 year
in-breast or nodal recurrence [11, 56]. These low figures are in keeping with the findings in this
current review.
It is difficult to make comparisons between recurrence rate following SLNB compared to SLNB +
ARM due to differences in how this was measured and the small number of studies which reported
this. Following SLNB, local recurrence was reported between 0 – 3.6% and systemic recurrence at 1.5
- 8%. Following SLNB + ARM, local recurrence was reported between 0 – 1.2% with distant
recurrence at 6.4%. From this data, it appears that recurrence rates are comparable for the two
procedures, but more evidence is needed in this area.
Other morbidity
The most common morbidity mentioned other than lymphoedema following ARM, was presence of
tattooing at injection site in the arm. Five of the studies, Kuusk U et al [20], Connor C et al [24], Deng
H et al [26], Noguchi M et al [27] and Boneti C et al [28], reported temporary tattooing at the injection
site for between a few days up to one year. Connor C et al [24] reported one case of skin necrosis at
the site of blue dye injection which resolved with topical wound care. No allergic reactions or other
problems were reported from method of ARM.
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It was commented on in the study by Ding X [19] that there was some trend towards improved arm
function in the group who had ARM success as opposed to ARM failure, however, this was not
statistically significant.
No other morbidities were specifically reported or had data collected on in any of the studies.
A large number of morbidities were reported following SLNB alone including increased pain,
decreased range of arm motion, change in sensation and seroma formation. These morbidities were
not frequently mentioned in the SLNB + ARM studies, although it was not the intention of any of the
SLNB + ARM studies to report this. As SLNB is a well-practiced procedure proven to be
oncologically safe (when compared with ALND), it is suspected that more recent studies have been
able to focus more on other reported morbidity following SLNB and that with time, this will be the
same of SLNB + ARM.
Feasibility/difficulties
In general, all studies were able to carry out the ARM procedures in their institution and this was
echoed in the systematic review [18]. The largest study in that review was the one presented by Ochoa
D et al [21] and they reported a lymphoedema rate of 2.5% for SLNB alone and 2% when ARM is
used. They propose that this very small difference suggests that the inability to identify ARM
lymphatics is not necessarily a ‘failed’ ARM procedure, but rather provides reassurance that
lymphatic drainages of the arm and breast are not in close proximity to the SLN and therefore, do not
pose risk of lymphoedema.
It is important to recognise that when performing the ARM procedure, the standard SLNB technique
of radioisotope and blue dye is not being used. Although in the majority of studies the SLN
identification rate was within expected levels, use of the ARM procedure in less experienced units
could result in lower SNB detection rates. A potential technique to overcome this would be the
administration of different radioactive tracers for the ARM and SNB procedure or by the addition of
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other dyes, for example indocyanine green, as in the studies by Sakurai T et al [22] and Noguchi M et
al [27], to replace the blue dye in the upper limb mapping.
Limitations
As already discussed, there were no studies identified comparing SLNB to SLNB + ARM, as per the
aim of this study, therefore, two sequential literature reviews were performed instead in order to
answer the study objectives.
This systematic review is limited in its ability to accurately assess lymphoedema outcomes using
ARM. The included studies used a range of definitions of lymphoedema, methodology of
measurement of lymphoedema and generally of low levels of evidence, making it difficult to draw
solid conclusions.
It is noted that many other factors affect rate of lymphoedema and these have not been specifically
examined in this systematic review, for example, adjuvant radiotherapy and chemotherapy, body mass
index, multiple surgeries.
It was not always possible in the studies to separate patients who had SLNB alone to those who had
SLNB and later went on to have ALND. This means that lymphoedema rates may have been
overestimated in this review.
There was only one systematic review included in search one and two included in search two, in this
analysis and no randomised controlled trials, thereby the evidence base for this review is generally
low.
Clinical relevance
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This literature review reveals that there is some evidence to support introduction of ARM in addition
to SLNB, in an attempt to reduce incidence of lymphoedema in breast cancer patients. ARM by a
variety of methods, appears feasible and has not posed any particular problems to individual
institutions. However, at present, it is unclear regarding the oncological safety of the procedure and
the impact ARM has on local and regional recurrence. Data regarding other potential morbidities such
as arm pain, sensory disturbance and reduced arm movements, is lacking. Therefore, at the present
time, this literature review does not show enough evidence to mandate the introduction of ARM into
current cancer guidelines.
Further work
In order to be able to introduce ARM into routine clinical practice, a large, randomised controlled trial
specifically comparing SLNB + ARM to SLNB alone should be performed. All breast cancer patients
who meet the criteria for SLNB would be eligible to participate. Participants would be randomised to
either receive routine care of SLNB alone or to have SLNB + ARM. Lymphoedema should be
measured by a well-defined, reproducible measure, by either water volume displacement or
circumferential arm measurements, in accordance with the international consensus ‘Best Practice for
the Management of Lymphoedema’ guidelines [30], as previously discussed. Arm
volume/circumference should be measured preoperatively and then at defined intervals
postoperatively, such as every 6 months. Length of follow-up must be adequate, for example, up to
five years. As well as lymphoedema, local and regional recurrence rate should be examined.
This would be an opportunity to examine other factors which firstly may impact on lymphoedema and
secondly may be an adverse feature of ARM procedure. Other factors include: administration of
chemotherapy and/or radiotherapy pre- and postoperatively; need for further surgery; patient body
weight/BMI; level of physical activity. Suggested adverse features of ARM may include: reduced arm
movements, sensory disturbance and increased arm pain.
Patients included in the study should be stratified by stage of cancer and by age.
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The benefit of this research would be the ability to counsel patients preoperatively on their
comparative risks of lymphoedema should they proceed with SLNB + ARM, compared to SLNB
alone, as well as possibility of metastatic involvement in crossover nodes and overall recurrence risk.
It is noted that there would be difficulties in performing a randomised controlled trial in this case for a
number of reasons. A large number of patients will need to be recruited to show clinical difference
between the two arms and patients would need to be followed up for a long time peroid. This is
because there are currently very low rates of regional recurrence following SLNB for N0 disease,
partly due to the efficacy of modern optimal adjuvant therapies. There is also a low rate of
lymphoedema already following SLNB for N0 disease. As previously mentioned there are many
discrepancies in the measurement of lymphoedema and this could propose a major bias to the study.
Conclusions
There is some evidence to support introduction of ARM in addition to SLNB for selected breast
cancer surgical patients. However, the current literature is of mainly low level evidence and casts
doubt over long-term oncological safety of ARM. Current studies are hampered by differing
methodology of performance of ARM and measurement of lymphoedema.
Therefore, a prospective randomised controlled trial is required to formally assess SLNB + ARM
compared to the current recommended axillary procedure of SLNB. This would be an opportunity to
take into account other factors which impact on development of lymphoedema such as body weight
and post-operative systemic treatments as well as to examine possible long-term negative
consequences of ARM.
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Legend to figures:
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Legends to tables:
Table 1: Search 1 - Demographics from full-text articles and abstracts
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Table 3: Search 2 – Results from full-text articles and abstracts
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Table 1: Search 1 - Demographics from full-text articles and abstracts
Date Study Context Lvl N Age
(yrs)
Stage Axillary
status
Primary
treatment
Method of SLNB Method of ARM Measurement of
lymphoedema
Dec
2015
Ahmed M
et al [18]
Systematic
review of ARM
used alongside
SLNB or
ALND
2 1142 SLNB or SLNB
+ ALND or
ALND
Majority used
radiolabeled
nanocolloid
subareolarly
Majority used 1-5ml
blue dye SC, SD or
IM in upper arm
Different definitions used
in each study
Dec
2014
Kuusk U
et al [20]
Single centre
prospective
study assessing
ARM to
preserve
lymphatics
3 52 56
(30-
74)
Locally
advanced
axillary
disease
excluded
28.8% known
nodal breast
cancer
metastases
Partial Mx
56.6%; total Mx
42%; SLNB +
ARM for N0
patients (n=37)
or ALND +
ARM for N+
patients (n=15)
Technetium-99
sulfur colloid
subareolar
1-2ml patent blue
dye into upper inner
arm
Circumferential
measurements of both
arms 15cm above elbow,
10cm below elbow, at the
wrist; defined as increase
of 2cm
Nov
2014
Ochoea D
et al [21]
Prospective,
non-randomized
cohort study to
evaluate
3 360 56 93.3%
invasive:
32.4%
positive:
Mastectomy or
lumpectomy.
SLNB + ARM
for N0 patients
Subareolar injection
of technetium sulfur
colloid and handheld
gamma probe
5ml blue dye SC in
volar surface of arm
Water volume
displacement
feasibility of
ARM and effect
on
lymphoedema
T1 67%;
T2
24.4%;
T3 6.5%
N1 76.1%; N2
15.5%; N3
8.3%
(n=237); ALND
+ ARM for N+
after positive
SLNB; (n=111);
ALND for N+
patients detected
preoperatively
(n=12)
May
2014
Sakurai T
et al [22]
Prospective
study to identify
at-risk groups
for
postoperative
lymphoedema
following ARM
+ SNB.
‘Corresponding
[C]’ group
displayed upper
extremity
lymphatic
3 321:
‘C’
76;
‘Non-
C’
245
‘C’:
59
(24-
80);
‘Non-
C’:
58
(28-
88)
‘C’:
Tis 16;
T1 39;
T2 19;
T3 2.
‘Non-C’:
Tis 54;
T1 131;
T2 52;
T3 8.
Clinically
negative
Surgery + SLNB
+ ARM for N0
patients (all
patients)
Preoperative
lymphoscintigraphy
and intraoperative
radioisotope
(99mTc-phytate) +
dye (indigocarmine)
ICG fluorescence
SC into interdigital
area and indigo
carmine blue dye
upper one third of
the arm
Bilateral arm
circumference based on
international consensus of
breast practices for
management of
lymphoedema. 1-2cm
expansion defined as mild
oedema and >2cm
drainage into
the breast SN
Mar
2014
Tummel
E et al
[23]
Prospective
assessment of
use of ARM as
a method to
reduce rates of
lymphoedema
in axillary
surgery
3 447 14 had
positive axilla
preoperatively
SLNB + ARM
for N0 (n=303);
ALND + ARM
for N+ after
positive SLNB
(n=130); ALND
+ ARM for N+
preoperatively
(n= 14)
Subareolar injection
of technetium
5mls lymphazurin
injected into upper
arm
Volume displacement
Oct
2013
Connor C
et al [24]
Prospective
non-randomised
trial to
investigate
ARM in a
population of
clinically node
negative and
node positive
3 184 60 SLNB all
clinically
negative;
ALND group
25% clinically
positive
SLNB + ARM
for N0 (n=155):
25% received
NAC, 22%
performed
during
prophylactic
mastectomy.
ALND + ARM
for N+ disease
Subareolar injection
of technetium sulfur
colloid and gamma
probe detection +
blue dye
2-5ml of blue dye
into dermal/SC
tissue into medial
intramuscular
groove
Bilateral measurements at
levels of meta-carpal
phalangeal joints, wrist,
10cm above the wrist, at
the elbow, 10cm above
the elbow; Increase >2cm
from baseline considered
positive.
breast cancer
patients
(n=57): 75%
followed NAC
Mar
2013
Kang S et
al [25]
Prospective
study to
investigate the
location and
metastatic rate
of the ARM
node and
evaluate
differences in
lymphoedema
3 116 ARM node
preserved: SLNB
+ ARM for N0
disease (n=10),
ALND + ARM
for N+ disease
(n=87); ARM
node
unpreserved:
SLNB + ARM
(n=4), ALND +
ARM (n=15)
2.5ml blue dye
injected into upper-
inner arm
Measured pre- and post-
operatively
Aug
2011
Deng H
et al [26]
Prospective
study to clarify
risk factors for
metastasis in
arm lymphatic
drainage in
breast cancer
3 69 47.99 0 2.9%;
I 44.9%;
IIa
46.4%;
IIb 5.8%
N0 73.9%;
N1 17.4%;
N2 7.2%;
N3 1.4%
BCS 80.5%;
SLNB + ARM
for N0 (all
patients)
0.5ml technetium-
99m nanocolloid to
nipple-areola
complex
1ml methylene blue
dye SC upper inner
arm along medial
intramuscular
groove
patients with
negative
axillary nodes
Mar
2010
M
Noguchi
et al [27]
A prospective
feasibility study
to improve
identification of
ARM nodes
and/or
lymphatics
3 20 63.3
(37-
85)
T1 40%;
T2 40%;
T3 15%;
T4 5%
N0 70%;
N1 15%;
N2 15%
Total Mx 11,
partial Mx 9;
SLNB + ARM
for N0 (n=12),
ALND + ARM
for N+ (n=8).
2mCI Tc-99m-
phytate into two
peritumoral sites;
lymphoscintigraphy.
0.1ml ICG
subdermally inner
wrist, 2ml ICG
subdermally upper
inner arm + near-
infrared
fluorescence
imaging system
Oct
2009
Boneti C
et al [28]
A prospective
study to assess
efficacy of
ARM to
preserve
lymphatics in
order to reduce
incidence of
lymphoedema
3 220 60.3
±
11.3
Clinically
negative
SLNB + ARM
for N0 (n=173),
ALND + ARM
for N+ (n=40)
Subareolar plexus
injection 1.0 mCI of
technetium sulfur
colloid
2-5ml blue dye
injected dermally
and then later SC
upper inner arm
Water volume
displacement: immerse
upper extremity to 10cm
above elbow.
Asymmetrical increase in
volume >20% from
baseline
Sept
2009
Casabona
F et al
[29]
Prospective
study to
evaluate
feasibility of
ARM during
SLNB
3 72 57
(25-
81)
SLNB:
T1a
15.9%;
T1b
27.0%;
T1c
57.1%
ALND:
T1c:
100%
Clinically
negative
Quadrantectomy
70.8%,
Mx 8.3%
WLE 20.8%;
SLNB + ARM
for N0 (n=63),
ALND + ARM
for N+ at SLNB
(n=9)
Subareolar injection
of 40 MBq
technetium-99m
nanocolloid.
2ml dermal blue
patent injected
intradermally, SC
and IM in upper
inner arm along
medial
intramuscular
groove
Circumferential
measurements.
Lymphangioscintigraphy
in patients who
underwent LYMPHA.
Measurements: starting at
olecranus, then at 5, 10
and 15cm intervals
distally and 5, 10, 15 and
20cm intervals
proximally.
Lymphoedema defined as
>1cm difference.
Abbreviations: ALND, axillary lymph node dissection; ARM, axillary reverse mapping; BCS, breast conserving surgery; CT, chemotherapy; ICG, indocyanine green; IM, intramuscular;
LYMPHA, lymphatic microsurgical preventing healing approach; Lvl, level of evidence; Mx, mastectomy; N, number of participants; NAC, neoadjuvant chemotherapy; SC, subcutaneous;
SD, subdermal; SLN, sentinel lymph node; SLNB, sentinel lymph node biopsy; Tis, in situ; WBI, whole breast irradiation; WLE, wide local excision
Table 2: Search 1 - Results from full-text articles and abstracts
Study Follow-up
(months)
Identification of
ARM
nodes/lymphatics
% of
crossover
(SLN =
ARM)
# of LNs
removed
Pathology
result ARM
nodes
Pathology
result
crossover
nodes
Rate of lymphoedema Other
morbidity
Recurrence
rate
Ahmed M
et al [18]
SLNB 4.3–
36;
ALND 6.3-
7.5
SLNB 27-100%;
ALND 78.3-
100%
SLNB 10% SLNB 0-5;
ALND 11-
13
SLNB 14-
20%;
ALND 0-
19%
SLNB 0-6%;
ALND 0-6%
SLNB: 1.2%
breast;
0.4% axillary
Ding X [19] 63.3% 8.3% 3.2% 40% Higher rate in group of
ARM failure (p<0.05)
ARM may
improve upper
limb function
Kuusk U et
al [20]
24 (6-36) 27% SLNB
5.4%;
SLNB 2.8;
ALND 11.5
SLNB
0%;
SLNB 2.1% (1/47) Blue tattoo
present for up
0%
ALND
13.3%
ALND
6.6%
to 1 year in
‘most’ patients
Ochoea D et
al [21]
Total 12
(13.6);
lymphoedema
assessment
10 (range 3-
48)
SLNB 33.7%;
ALND 75.4%
SLNB
4.3%
18.5% 14.3% Overall:
Subjective 8.4% (20/238);
objective 2.9% (7/238):
SLNB 2.5% (4/158), ALND
3.7% (3/80)
Subjective
complaints of
‘lymphoedema’
resolved with
pain
management
Distant
6.4%; local
1.2%
Sakurai T et
al [22]
28 (12-47) 32.3% 20.7%
(Non-C
group)
‘C’: 1.51 (1-
6).
‘Non-C’:
1.80 (1-6)
‘C’: 5/76
‘Non-C’: 0/245
This was statistically
significant
Lymphoedema
more likely
associated with
post-operative
CT and WBI
Tummel E
et al [23]
24 (3-54) SLNB 33.3%;
ALND 77%
SLNB 3%;
ALND
14%
SLNB
0%;
ALND
15%
SLNB 0.33%; ALND 5.5% SLNB 0%,
ALND 0.7%
Connor C et
al [24]
12 SLNB 47%;
ALND 72%
SLNB
12%;
ALND
10%
SLNB 3;
ALND 20
SLNB 0%;
ALND 18%
SLNB
0%;
ALND
25%
SLNB 4% (6/137) One patient
experienced
skin necrosis at
site of blue dye
injection at
upper inner
arm (0.5%)
Kang S et al
[25]
16.24 (3-24) Mean number of
identified blue
stained nodes
1.41 +/- 0.66
1.41  0.66 Unpreserved:
4.3%
SLNB: no difference
between preserved and
unpreserved group
ALND: arm circumference
greater in arm unpreserved
group (p=0.066); 0% ARM
node preserved group, 5.2%
unpreserved group.
0%
Deng H et
al [26]
27.5% 8.7% 31.6% Mild blue mark
at injection site
for up to 4
weeks in the
‘majority’ of
patients
M Noguchi
et al [27]
10 days SLNB 75%
ALND 88%
14% SLNB 1.2
(1-2);
ALND 23.5
(13-45)
SLNB 0%;
ALND 43%
0% Temporary
tattoo at
injection site
for up to 10
days
0%
Boneti C et
al [28]
6 SLNB 40.6%;
ALND 47;
SLNB + ALND
40 (18.7%)
2.8% ALND 12.7
+/- 5.6
SLNB 0% 0% 5.4% overall;
0% SLNB
Temporary
tattoo for up to
few months in
‘most’ patients
Casabona F
et al [29]
9 SLNB 37.5%
ALND 88.9%
SLNB 1.3
ALND 16
(9-24)
0% 0% (0/72) 0%
Abbreviations: ALND, axillary lymph node dissection; ARM, axillary reverse mapping; BCS, breast conserving surgery; CT, chemotherapy; ICG, indocyanine green; IM,
intramuscular; LYMPHA, lymphatic microsurgical preventing healing approach; Lvl, level of evidence; Mx, mastectomy; N, number of participants; NAC, neoadjuvant
chemotherapy; SC, subcutaneous; SD, subdermal; SLN, sentinel lymph node; SLNB, sentinel lymph node biopsy; Tis, in situ; WBI, whole breast irradiation; WLE, wide local
excision
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Table 3: Search 2 – Results from full-text articles and abstracts
Date Study Context Lvl N Stage Axillary
treatment
Method of SLNB Measurement of
lymphoedema
Follow-
up
(months)
Rate of
lymphoedema
Other
morbidity
Recurrence
rate
Dec
2015
Voss R et al
[30]
Prospective
cohort study to
investigate risk
factors for
lymphoedema in
breast cancer and
melanoma
3 205 0 8%;
I 43%;
II 31%;
III 12%;
IV 3%
SLNB for N0
disease (n=107),
ALND for N+
disease (n=98)
According to
surgeon’s preference
Perometry
measured at 9, 6,
12 and 18
months.
Moderate/severe
lymphoedema
defined as limb
volume change
10%
18 36.5% overall Upper-
extremity
numbness,
tightness,
aching,
swelling,
stiffness and
heaviness
Jun
2015
Li J et al
[31]
Prospective
study
investigating
accuracy of
SLNB compared
to partial ALND
3 289 SLNB for N0
(n=221), partial
ALND
following
positive SLNB
(n=59), partial
ALND due to
failed SLNB (n-
9), partial
ALND for
Methylene blue dye
into tumour bed/areola
Arm
circumference at
the point of 10cm
proximal to the
medial
epicondyle
before surgery
and at 12 months.
Severe
lymphoedema
12-33 0% following
SLNB
Overall
survival
97.2%;
death 3%;
local
recurrence
0%
patient choice
(n=149)
diagnosed at
increase 2cm
Jun
2015
Gebruers N
et al [32]
Systematic
literature review
to assess
incidence of
lymphoedema in
node-negative
breast cancer
2 9588 SLNB for N0
(all patients)
Variety of
methods, at 3,
6, 12, 18 or >18
months
0-63.4%
Dec
2014
Fu Y et al
[33]
Retrospective
analysis of
primary breast
cancer patients
undergoing
SLNB or ALND
3 214 T1
46.2%;
T2
44.3%;
T3
6.6%;
Tx
2.8%
SLNB for N0
(n=39), ALND
for N+ (n=112)
Peritumoral/periareolar
injection of 99m Tc-
labeled sulfur colloid
and 1% isosulfan blue
dye
Self-reported as
well as
circumferential
measurement of
both arms at
wrist, forearm
and upper arm
Median
43.6
7.7% following
SLNB
Pain, limited
range of
motion
Local
recurrence
0%
Oct
2014
Fu M et al
[34]
Prospective
cohort study to
investigate
lymphoedema
risk reduction
measures
3 134 SLNB for N0
(n=59), ALND
N+ (n=75)
Perometer at
baseline, 2-4
weeks, 6 months
and 12 months.
Lymphoedema
3% at 2-4
weeks
following
SLNB
defined as
increase 10%.
Aug
2014
Black D et al
[35]
Retrospective
study to
determine racial
differences in
SLNB use
among patients
with node-
negative breast
cancer
3 27856
white, 1767
black
SLNB for N0
(n= 20530 white
population,
1103 black
population);
ALND for N+
Variety of
methods
5 years 6.8% white
population;
8.8% black
population
following
SLNB
Aug
2014
Gärtner R et
al [36]
Retrospective
review of follow-
up questionnaire
study looking at
lymphoedema in
primary breast
cancer patients
3 2293 SLNB for N0
disease +
chemotherapy
(n=45) or
without
chemotherapy
(n=61), ALND
for N+
Questionnaire:
‘Does the armpit,
the arm of the
back of the hand,
on the side where
you were
operated,
sometimes or
always feel
swollen or
heavy?’; severity
on 0-10;
9-11
years
SLNB +
chemotherapy
17%; SLNB
alone 10%
frequency of
symptoms
May
2014
Sánchez P et
al [37]
Retrospective
observational
study to analyse
lymphoedema in
breast cancer
patients
undergoing
SLNB
3 145 SLNB for N0
(all patients)
8.4% Seroma
May
2014
Sagen A et
al [38]
Prospective
cohort study to
examine upper
limb function
following ALND
and SLNB
3 391 Early-
stage
primary
breast
cancer
SLNB for N0
(n=161), ALND
for N+
 ≥10% increase in 
arm volume
relative to control
arm volume
defined as
lymphoedema
2.5 years 3% following
SLNB
Grip strength
reduction,
shoulder
abduction-
provoked
pain
Feb
2014
Miller C et
al [39]
Prospective
study evaluating
rates of
lymphoedema in
mastectomy
patients
3 664 SLNB for N0 +
no radiotherapy
(n=34), SLNB +
radiotherapy
(n=58), ALND
for N+ no
radiotherapy
Perometer arm
volume
measurements
pre and post-
operatively;
lymphoedema
defined as ≥10% 
2 years SLNB +
radiotherapy
10%; SLNB
alone 2.19%
(n=229), ALND
+ radiotherapy
(n=229)
increase in arm
volume
Jan
2014
Morcos B et
al [40]
Prospective
cross-sectional
study assessing
risk factors for
developing
lymphoedema
following breast
cancer
3 499 SLNB for N0
(n=90), ALND
for N+
Mid-arm of
forearm
circumference
difference
between both
limbs of 2cm of
more
26.2 4.5% following
SLNB
Sept-
Oct
2013
Burger A et
al [41]
Retrospective
review of
prospectively
maintained
database of
patients
undergoing risk
reducing
mastectomy
3 83 SLNB for N0
(all patients)
0%
May
2013
DiSipio T et
al [42]
Literature review
assessing
lymphoedema
2 18 studies Variety of
methods
5.6% following
SLNB
following breast
cancer
Mar
2013
McLaughlin
S et al [43]
Prospective
study evaluating
lymphoedema
following ALND
and SLNB
3 120 SLNB for N0
(n=67), ALND
for N+ (n=53)
Circumferential
measurement at
4cm increments
from nail bed
base of middle
finger to axillary
fold
3% at 12
months
following
SLNB
Feb
2013
Wernicke A
et al [44]
Retrospective
review of stage I-
II breast cancer
patients
investigating
complication
rates
3 226 TI
82%,
T2
18%
SLNB for N0
(n=111), ALND
for N+ (n=115)
Objective
measurement at
baseline and each
follow-up visit at
antecubital fossa,
10cm superior,
10cm inferior
and at the wrists.
Lymphoedema
defined as
difference >1cm.
9.4 years
(8.6 –
15.2)
5.4% following
SLNB
Axillary web
syndrome,
seroma,
wound
infection,
decreased
range of
shoulder
movement,
paraesthesia
In-breast
recurrence
3.6%; distant
metastases
1.5%.
Jun
2012
Ozcinar B et
al [45]
Prospective
observational
study to examine
3 218 Early
stage
SLNB for N0
(n=80), ALND
for N+ (n=138)
10cm proximal
and distal to
olecranon, pre
Median
64
8% following
SLNB
lymphoedema in
early-stage breast
cancer patients
and post-
operative
measurements.
Lymphoedema
defined as >2cm
increase
Nov
2011
El-Asir L et
al [46]
Retrospective
analysis of
patients
undergoing
SLNB and/or
ALND to
determine
incidence of
lymphoedema
3 678 SLNB for N0
(n=365), ALND
for N+ (n=313)
0.2% following
SLNB
Aug
2011
Aslani N et
al [47]
Retrospective
review of
prospectively
collected
database
comparing
patients
undergoing
SLNB with
3 185 T1
54.7%;
TII
41.1%;
TIII
3.2%;
TIV
All patients N+
at SLNB.
Patients
undergoing no
further
procedure
(n=95) or
ALND (n=90).
36
(median
1.9 years)
7% following
SLNB
Pain,
tethering or
stiffness in
the axilla,
radiation
pneumonitis
Locoregional
recurrence
1%,
systemic
recurrence
8%
completion
ALND
1.1%
Jan-
Feb
2010
Helyer K et
al [48]
Prospective
study to
determine
predictors of
lymphoedema in
patients
undergoing
SLNB +/- ALND
3 137 SLNB for N0
(n=52), ALND
for N+ (n=31),
ALND for N0 to
detect false-
negative (n=54)
Radioactive colloid
and/or isosulphan blue
dye.
Lymphoscintigraphy
for patients who
underwent radioactive
colloid injection.
Arm volume
measurements
preoperatively
and then every 6
months: arm
submersed in
10cm above
olecranon and
volume recorded.
Lymphoedema
defined as
measurement
changes of
>200cc.
Median
20 (6 –
36)
37.5%
following
SLNB
Nov-
Dec
2009
Lumachi F
et al [49]
Retrospective
review of
patients who
underwent
curative surgery
for primary
breast cancer
3 205 SLNB for N0
(n=54), ALND
following
positive SLNB
(n=48) using
ultrasound
scissors, ALND
for N+ using
3.7% following
SLNB
ultrasound
scissors (n=53),
ALND for N+
by traditional
methods (n=50)
Nov
2008
McLaughlin
S et al [50]
Prospective
study to compare
incidence of
lymphoedema in
patients
undergoing
SLNB compared
to SLNB +
ALND
3 936 Tis
13%;
TIa
17%;
TIb
26%;
Tic
35%;
TII
8.3%
SLNB for N0
(n=600), ALND
for positive
SLNB (n=336)
Technetium-labeled
sulfur colloid
intradermally +
isosulfan blue dye
intraparenchymally
Circumferential
measurements
10cm above and
5cm below
olecranon
process,
preoperatively
and at follow-up
3 to 8 years later.
Lymphoedema
defined as >2cm
increase at any
location. Severe
lymphoedema at
>5cm increase.
Median 5
years (2.7
– 8 years)
5% following
SLNB
Nov
2006
Francis W et
al [51]
Prospective
study
investigating
incidence and
3 209 SLNB for N0
(n=41), ALND
for N+ (n=105)
Blue dye +
radioisotope
Circumferential
arm
measurements at
10cm intervals
12 16.8% after
SLNB
severity of
lymphoedema
during the first
year after SLNB
and ALND
starting at the
hand. Measured
quarterly for 12
months.
Lymphoedema
defined as
increased
measurement by
at least 5%.
Apr
2006
Wilke L et al
[52]
Prospective
multicentre trial
to investigate
prognostic
importance of
micrometastases
in SLNB in early
stage breast
cancer
3 4069 SLNB for N0
(all patients)
Blue dye, or
radioisotope or blue
dye + radioisotope
Measurement at
10cm proximal
and distal to
medial
epicondyle,
compared to
preoperative
measurement.
Defined as
increase >2cm.
6 7% Wound
infection,
haematoma,
seroma,
brachial
plexus injury
Abbreviations: ALND, axillary lymph node dissection; Lvl, level of evidence; N, number of participants in study undergoing SLNB; SLNB, sentinel lymph node biopsy; Tis, in situ; Tx stage unknown

